Recurrent Glioblastoma Multiforme Treatment Market Higher Mortality Rates by 2027

The growing incidence of brain tumors is projected to foster the expansion of the worldwide glioblastoma multiforme market during the forecast period. As per the National Foundation for Cancer Research, GBM is that the deadliest sort of brain cancer, accounting for 45% of all malignant brain tumors. Furthermore, consistent with the article published by the National brain tumour Society, over 10% of individuals with brain tumors are at high risk of developing glioblastomas. Additionally, key players within the market are involved in joint ventures and partnerships to develop and commercialize novel drugs, so as to strengthen their business within the global glioblastoma multiforme market. as an example , in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM.

The PDF for the study can be requested using the following link:

North America is predicted to dominate the worldwide glioblastoma multiforme market and this is often attributed to the increasing drug approvals and launches for GBM treatment is again expected to spice up the expansion of the worldwide glioblastoma multiforme treatment market. as an example , in January 2020, Pfizer launched ‘Zirabev’ within the U.S., which may be a bevacizumab biosimilar of Avastin, approved for the treatment of recurrent glioblastoma multiforme. The biosimilar was approved by FDA in June 2019 for the treatment of metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma multiforme, recurrent/persistent or metastatic cervical cancer, and metastatic renal cell carcinoma.

1. In October 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical test evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients

2. In March 2018, the Australia-based Kazia Therapeutics, a biopharma company, started phase II clinical trial clinical trials within the U.S. for its drug, GDC-0084. it’s a completely unique vaccine, Rindopepimut, is in last-stage development in Australia and India for first-line GBM treatment

3. In December 2020, CNS Pharmaceuticals, Inc. announced that FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme

Glioblastoma Multiforme is that the second most serious of all the gloom, a gaggle of generally benign tumors growing within the intracranial cavity or their central systema nervosum , usually within the jaw area. Generally diagnosed when symptoms are noticed, GBM usually grows slowly and over time. Clinically, glioblastomas are classified into four different grades; however, the third most serious, grade 4 or GBM, is that the commonest in citizenry . Like all other sorts of cancer, the primary stage of GBM is typically the smallest amount dangerous, though it’s going to produce symptoms that are indicative of other, more serious conditions. The third and fourth stages of GBM are considered more dangerous thanks to the more frequent emergence of secondary sites and therefore the increased ability for secondary GBM to migrate.

Competitive Landscape

Key players operating in the recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., B oehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.

“Limited Time Offer”

We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027


About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformation growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Related Articles

Back to top button